NCT00406809 - A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions

Chronic Lymphoid LeukemiaLymphoid MalignanciesNon-Hodgkin's LymphomaFollicular LymphomaMantle Cell LymphomaPeripheral T-cell Lymphoma

Interventions

DRUG

ABT-263

"Oral solution~Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.~Oral solution and tablets~Phase 2a dosing under 21 day continuous dosing.~\- 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose."

Trial Locations (12)

10016

Site Reference ID/Investigator# 23543, New York

10021

Site Reference ID/Investigator# 2627, New York

10032

Site Reference ID/Investigator# 2614, New York

10065

Site Reference ID/Investigator# 5383, New York

14263

Site Reference ID/Investigator# 2628, Buffalo

14642

Site Reference ID/Investigator# 12306, Rochester

20892

Site Reference ID/Investigator# 2613, Bethesda

90033

Site Reference ID/Investigator# 4997, Los Angeles

90095

Site Reference ID/Investigator# 9104, Los Angeles

02215

Site Reference ID/Investigator# 40243, Boston

Site Reference ID/Investigator# 4745, Boston

T6G 1Z2

Site Reference ID/Investigator# 8941, Edmonton

All Listed Sponsors

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY